



ABN 53 075 582 740

ASX ANNOUNCEMENT

12 November 2014

Bionomics Limited (ASX:BNO, ADR: BMICY) hereby gives notice to the Australian Securities Exchange ("ASX") that shareholders of the company passed all resolutions considered before the Annual General Meeting today.

The Notice of Annual General Meeting and accompanying documents were lodged with ASX on 10 October 2014.

This notice is given in accordance with ASX Listing rule 3.13.2 and section 251AA of the Corporations Act 2001.

Resolution Number	Resolutions	Result	Proxy Votes			
			For	Against	Abstain	Proxy's discretion
1	Adoption of Remuneration Report	Passed on a Poll	152,315,757	44,542,345	691,859	10,173,117
	The motion was carried as an ordinary resolution on a poll, the details of which are:		162,801,068	44,587,345	691,859	
2	Re-election of Non-Executive Director – Mr Trevor Tappenden	Passed on a show of hands	196,752,406	679,808	1,586,274	10,276,238
3	Approval of Proposed Issue of Share Options to Dr Deborah Rathjen - Y/E 30 June 2014	Passed on a show of hands	152,476,828	44,634,338	2,086,947	10,096,613
4	Approval of Bionomics Limited Employee Share Plan	Passed on a show of hands	153,077,227	45,402,536	646,846	10,168,117
5	Approval of Bionomics Limited Employee Share Option Plan	Passed on a show of hands	147,497,458	50,972,305	658,846	10,166,117

FOR FURTHER INFORMATION PLEASE CONTACT:

Bionomics Limited

Dr Deborah Rathjen
 CEO & Managing Director
 +61 8 8354 6101 / 0418 160 425
drathjen@bionomics.com.au

Ms Melanie Young
 CFO & Company Secretary
 +61 8 8354 6107 / 0414 264 547
myoung@bionomics.com.au

About Bionomics Limited

Bionomics (ASX: BNO) is biopharmaceutical company which discovers and develops innovative therapeutics for cancer and diseases of the central nervous system. Bionomics has small molecule product development programs in the areas of cancer, anxiety, memory loss and pain. Its oncology approach includes cancer stem cell therapeutics as well as vascular disruption in solid tumours. Bionomics partners include Merck & Co.

Bionomics' discovery and development activities are driven by its four proprietary technology platforms: MultiCore®, a diversity orientated chemistry platform for the discovery of small molecule drugs; ionX®, a set of novel technologies for the identification of drugs targeting ion channels for diseases of the central nervous system; Angene®, a drug discovery platform which incorporates a variety of genomics tools to identify and validate novel angiogenesis targets (involved in the formation of new blood vessels); and CSC Rx Discovery™, which identifies antibody and small molecule therapeutics that inhibit the growth of cancer stem cells. These platforms drive Bionomics' pipeline and underpin its established business strategy of securing partners for its key compounds.

www.bionomics.com.au